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Abstract
The myasthenic syndrome in children can be inherited or of acquired autoim-
mune origin. In the autoimmune syndrome, babies born to a myasthenic mother 
are floppy at birth with weak cry, ptosis, and impaired respiration. Fortunately, 
most of these cases are transient and complete recovery will take place after few 
weeks; however, good supportive measures are needed until recovery. On the 
other hand, the classical autoimmune myasthenia gravis (MG), which is known as 
juvenile myasthenia gravis, can occur in children of any age group. It is commonly 
divided into prepubertal and postpubertal, the latter usually follows adult criteria, 
is more common in females, generalized, and most of them are seropositive for 
neuromuscular antibodies. In contrast, in acquired myasthenia gravis that occurs 
in prepubertal children, there is no sex predilection and patients are less likely 
seropositive, and ocular myasthenia more likely to occur than postpubertal. An 
interesting group of childhood myasthenic syndromes is the congenital myasthenic 
syndrome; this is an uncommon, nonimmune-mediated heterogeneous syndrome 
with variable presentation, ranging from mild symptoms with little weakness to 
severe ones that may cause extreme weakness and respiratory failure. Congenital 
myasthenic syndrome is classified into presynaptic, synaptic, and postsynaptic, 
and each of them has subtypes, with the postsynaptic syndrome representing 
the most common type. Many patients with congenital myasthenic syndrome are 
misdiagnosed with seronegative acquired myasthenia or congenital myopathy; 
however, advances in disease investigation are showing promise in early and 
precise diagnosis.
Keywords: myasthenia gravis, congenital myasthenic syndrome, neonatal 
myasthenia
1. Introduction
Myasthenia gravis in children generally is not uncommon disease, either it is 
genetic type known as congenital myasthenia syndrome (CMS) that involve struc-
tural defect of neuromuscular junction [1]. It is significant that is included in the 
differential diagnosis of seronegative myasthenia gravis (MG), congenital myopa-
thy, peripheral neuropathy, and childhood and adolescent motor neuron diseases.
The prevalence rates of acquired autoimmune myasthenia gravis on the other 
hand have been increasing in the last two decades, with approximately 20 cases 
per 100,000 in the US population. In this syndrome, autoantibodies act against the 
neuromuscular junction (NMJ) [2].
Furthermore, there is another type of syndrome called transient neonatal 
myasthenia in which there is a passive transfer of autoantibodies from a mother 
with myasthenia gravis (MG).
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The primary manifestation is weakness typically with diurnal fluctuation; 
nevertheless, variant or atypical presentations must also be considered and appro-
priately recognized.
MG is suspected from clinical and neurological examinations, particularly 
fatigue test. Moreover, investigation tools like electromyography (EMG) with 
repetitive stimulation tests and special instances may need the use of single fibers.
In general, advances in intensive care, therapy, and the use of immunomodula-
tory agents are improving the quality of life of patients with MG.
2. Congenital myasthenic syndrome
Congenital myasthenic syndrome (CMS) is a genetic disease, inherited as 
autosomal recessive, nonimmunologic neuromuscular disorder, with a prevalence 
of about 1/200,000. Its onset occurs usually at infancy, although sometimes its 
presentation can be delayed to young adulthood. Weakness along with fatigue is 
major presentation of CMS, and repetitive nerve stimulations have revealed dec-
remental response in CMS patients in the absence of antibodies against muscle or 
neuromuscular junction [1, 3].
3. Classification of congenital myasthenic syndrome
Usually classified according to the defective site of the neuromuscular junction, it 
is often divided into presynaptic, synaptic, and postsynaptic disorders (Table 1) [4].
Presynaptic CMS: the prototype is CMS with episodic apnea, which is genetically 
determined as mutations in the enzyme choline acetyltransferase (ChAT) [5, 6].  
Moreover, other presynaptic disorders have been detected that have a paucity of 
synaptic vesicles release with features resembling the autoimmune Lambert-Eaton 
myasthenic syndrome [7].
Synaptic CMS: solely related to acetylcholinesterase (AChE) deficiency in which 
there are mutations in COLQ, it is the second most common cause of CMS (about 
15%), coding for the collagen-like tail of the AChE molecule [8, 9].
Congenital 
myasthenic 
syndrome 
(CMS)
Presynaptic defects (5%) Synaptic defect (basal 
lamina) (15%)
Postsynaptic 
defects (80%)
Choline acetyltransferase 
deficiency
Paucity of synaptic vesicles
Congenital Lambert-
Eaton-like syndrome
Other unclassified 
presynaptic defects
Endplate acetylcholinesterase 
deficiency
Reduced AChR 
expression
AChR mutations
Rapsyn mutations
DOK-7 mutations
AChR kinetic 
abnormality
Slow-channel 
syndrome
fast-channel 
syndrome
Sodium-channel 
mutations
AChR, acetylcholine receptor.
Table 1. 
Classification of congenital myasthenic syndromes [7, 15].
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Postsynaptic CMS: in which a variety of genes have been detected to encode the 
AChR subunits, resulting in defects in AChR function or AChR subunit deficiencies 
like congenital myasthenia associated with Dok-7 deficiency and sodium-channel 
myasthenia or their combinations. In general, AChR mutation represents the 
majority of CMSs, about 75–85% [1, 3, 10, 11]. Furthermore, mutations in the genes 
for rapsyn and muscle-specific receptor tyrosine kinase (MuSK) reduced AChR 
expression and are considered an important cause of postsynaptic CMS [12].
4. Clinical presentations of congenital myasthenic syndromes
There are no constant clinical features for the diagnosis of CMS, and it is based 
on the age of presentation and type of neuromuscular defect; however, a nonspecific 
clue of the syndrome might be evident prenatally, which is reduced fetal movement. 
Neonates and infants with CMS experience generalized weakness, delayed motor 
milestone, and hypotonia with an evidence of wasted muscle bulk over time along 
with an evidence of exertional weakness and fluctuation of weakness, which gets 
worse with intercurrent infection. Various skeletal deformities are usually observed 
like high-arched palate, dysmorphic facial features, arthrogryposis, and scoliosis [4].
4.1 Presynaptic CMS
4.1.1 Congenital myasthenic syndrome with episodic apnea
Congenital myasthenic syndrome with episodic apnea represents an exemplary 
standard of presynaptic CMS, an autosomal recessive disorder with mutations in 
the gene encoding choline acetyltransferase (ChAT) [4].
The baby is described at birth as floppy with irregular breathing and difficulty 
in feeding. Examinations show ptosis with mild extraocular muscle weakness; 
however, the baby experiences recurrent apneic episodes, which is considered as 
a hallmark of this disorder. Nonetheless, apneic episodes may occur with other 
types of CMSs also; so, CMS with episodic apnea may be a misnomer. Prolonged 
apnea may lead to brain damage due to hypoxia. The apnea is usually precipitated 
by stressful conditions like fever, infection, and exertion. Therefore, CMS must be 
considered in differential diagnosis in families with history of sudden infant death. 
The apnea in this type of CMS decreases with advancing of age and will respond to 
anticholinesterase medication such as pyridostigmine prophylaxis [4].
Although EMG remains the initial diagnostic procedure in suspected cases, it 
often shows normal repetitive nerve stimulation at low rate (3 Hz), and single-fiber 
EMG (SFEMG) is usually normal. But a decremental response is found at prolonged 
exertion or high-rate (10 Hz) repetitive nerve simulation [4].
4.2 Synaptic CMS
4.2.1 Congenital acetylcholinesterase (AChE) deficiency
Congenital acetylcholinesterase (AChE) deficiency is an autosomal recessive dis-
order that presents with hypotonia and weakness that is often significant and involves 
the face. There are also delayed motor millstones, feeding difficulties, and, sometimes, 
skeletal deformities like scoliosis. Moreover, the patient may have peculiar finding 
such as pupillary hyporeflexia and progressive myopathy. Unfortunately, the patient 
does not respond or may get worse with anticholinesterase or other medication that is 
used for other types of CMS; however, some cases respond to ephedrine [13].
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EMG displays usual features of neuromuscular disorders with decremental 
compound muscle action potential (CMAP) with repeated nerve stimulation in 
addition to jitter with single-fiber electromyography (SFEMG). On the other hand, 
there is an interesting EMG finding, which occurs in AChE deficiency in addition to 
the slow-channel syndrome, and this is repeated CMAP in response to single nerve 
stimulation.
The pathophysiology behind that is prolonged exposure of acetylcholine (Ach) 
to its receptor due to defect in its destruction by absence or defect in AChE, in 
consequence there is muscle membrane depolarizing block [14, 15].
4.3 Postsynaptic CMS
The postsynaptic CMS is considered the most common type of CMS and is 
caused by gene mutations that encode AChR subunits. In consequence, there is a 
defect in ion-channel gating and or a decrease in number of receptors resulting in 
slow-channel, fast-channel, or AChR deficiency syndrome; in addition, the muta-
tion may be in the rapsyn, MuSK, or Dok-7, resulting in neuromuscular junction 
disorders [11, 16].
4.3.1 AChR deficiency
AChR deficiency is inherited as autosomal recessive with mutation in genes that 
encode AChR subunits in the postsynaptic neuromuscular junction. Clinically, the 
patient presents early in infancy with variable severity; the child experiences motor 
developmental delay, ptosis, limitation of extraocular movement, and impaired 
feeding. However, it is not progressive, and weakness improves to some extent when 
the child becomes older.
EMG displays typical myasthenic syndrome features that include decremental 
CMAPs at low-rate (3 Hz) stimulations and increasing jitters with block in single-fiber 
EMG [17].
4.3.2 Kinetic abnormality of the AChR
The functional character and kinetic properties of AChR may be impaired as a 
result of mutation in AChR deficiency gene, particularly when AChR is not signifi-
cantly reduced. Slow-channel and fast-channel CMSs represent the main kinetic 
abnormalities of the AChR.
4.3.2.1 Slow-channel congenital myasthenic syndrome (SCCMS)
SCCMS is considered the most common type of CMS [1]. The primary patho-
genesis is increased duration of channel opening resulting from kinetic impairment 
of AChR. In consequence, there is slowing of the rate of channel closure with an 
increase in the rate of channel opening; moreover, sometime increase receptor-
AChE affinity resulting in depolarizing neuromuscular block and weakness with 
exertion. It is an autosomal dominant inheritance with variable penetrance and 
expression in most cases; however, autosomal recessive inheritance has also been 
reported [18, 19]. Its presentation had variable severity and variable age of onset 
from early infancy, which could be delayed to teenage. Clinical manifestation is 
characterized by muscular weakness and wasting involving neck and scapular and 
extensor muscles of finger. Ptosis and extraocular muscle involvement mild or 
spared. The circumstances have been different from other types of CMS, this type 
usually progressive although its slowly, furthermore respiratory muscle and other 
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muscles particularly upper limb, intrinsic and fingers extensor muscles in addition 
to bulbar muscles are regularly involved [19].
EMG must be done to the involved muscle for sensitive results; and usually, 
it shows decremental CMAP in low-rate (3 Hz) stimulations. Interestingly, like 
endplate AChE deficiency, single-nerve stimulation usually but not always shows 
unique repetitive CMAP response [20].
SCCMS must be considered in the differential diagnosis of congenital muscu-
lar dystrophy, congenital myopathy, autoimmune-type MG, and metabolic and 
mitochondrial myopathy.
Patients with SCCMS like AChE deficiency get worse with the use of cholinester-
ase inhibitors due to enhanced desensitization of receptors via prolonged endplate 
current, which gives clue to differentiate this syndrome from autoimmune MG; 
however, if the patient does not receive treatment, the symptoms get worse in con-
sequent years. Quinidine and fluoxetine are considered the medication of choice, 
their action on decrease opening of AChR channel [21, 22]. The dose of quinidine is 
200 mg; when given twice or three times per day, it leads to improvement in short- 
and long-term weakness and even improved nerve conductivity as detected by EMG 
follow-up. In practice, fluoxetine with a dose of 80–160 mg per day is preferable as 
it has less side effects with same effectiveness as quinidine [15].
4.3.2.2 Fast-channel congenital myasthenic syndrome
Fast-channel congenital myasthenic syndrome is an autosomal recessive inheri-
tance and has common features with AChR deficiency syndromes; however, it is more 
severe. The pathophysiology disparity to SCCMS in which Ach., when bound to Ach 
receptor, the time of channel opening is short, in consequence the activation become 
short resulting in decrease transmission of signals [11, 23, 24]. Clinically, it is like other 
CMSs presenting with delayed motor milestones, ptosis, limitation of extraocular 
movement with difficulties in feeding and chewing, and also fatigue and generalized 
weakness triggered by exertion [25]. Nonetheless, mild cases may be missed clinically 
and even via EMG procedures and erroneously diagnosed as congenital myopathy. In 
contrast, the severe cases experience respiratory distress, facial involvement or even 
arthrogryposis multiplex features [1]. Of note, fast-channel CMS must be considered 
in differential diagnosis of patients with seronegative myasthenic syndrome.
EMG findings show typical symptoms of postsynaptic neuromuscular disorders 
that include decremental CMAPs at repetitive low-rate simulations (3 Hz), increased 
jitter with block in single-fiber EMG, and no observation of repetitive CMAPs.
Fortunately, the patient benefits from the use of cholinesterase inhibitors and 
3,4-diaminopyridine or both [26] and if left without treatment may experience 
slowly progressive disease or remain stationary.
4.3.3 Mutations affecting acetylcholine receptor (AChR) clustering and synaptic 
structure
To achieve effective synaptic transmission, there must be functional and struc-
tural integrity of all involved neuromuscular postsynaptic parts [27].
4.3.3.1 AChR deficiency due to receptor-associated protein of the synapse 
(RAPSN) mutations
AChR deficiency due to receptor-associated protein of the synapse (RAPSN) 
mutations may occur at any age; nevertheless, neonates are the most commonly 
affected and might need nasogastric tubes for feeding and mechanical ventilation 
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due to severe hypotonia and significant bulbar involvement. Sometimes, the baby 
is born with arthrogryposis multiplex, but the condition improves with advancing 
age with less probability of apnea. It is sometimes misdiagnosed as seronegative 
acquired autoimmune myasthenia gravis. Ankle dorsiflexion weakness is considered 
a characteristic feature of this syndrome and might give hint for the diagnosis [28].
EMG; as other myasthenic syndrome show decremental CMAP and jitter in 
single fiber. Nevertheless, sometimes, there is difficulty in detection of these typical 
features in EMG.
Fortunately, those patients respond to anticholinesterase agents and may get 
additional improvement from 3,4-diaminopyridine [28].
4.3.3.2 Congenital myasthenic syndrome with proximal weakness due to mutations 
in DOK7
This syndrome is sometimes called limb girdle CMS as proximal muscle weak-
ness is more than that of the distal one [29]. Although the patient initially attained 
millstones on time, but the patient might have ptosis since early infancy and could 
be progressive on the other hand in childhood age experience progressive weak-
ness with predominant proximal muscle weakness and may lead to nonambulation 
state. Fifty percent of patients display tongue atrophy and ptosis which might be 
progressive, but often still no ophthalmoplegia and the fluctuation of symptoms are 
predominant nevertheless a lot of patients misdiagnosed as myopathies [30, 31].
4.3.3.3 Mutations in CHRNG neuromuscular transmission
Mutations in CHRNG neuromuscular transmission is caused by prenatal 
inherited myasthenia, which in consequence might result in fetal developmental 
abnormalities [32].
Escobar’s syndrome (multiple pterygium syndrome) is the most well-known 
type of CMS attributed to CHRNG mutation. It is inherited as autosomal recessive 
with cranial deformities including ptosis, low-set ear, high-arched palate, receded 
chin, and orthopedic deformities including arthrogryposis multiplex and cervical 
pterygia; in addition, many of them die in the uterus [33].
4.3.3.4 MuSK mutations postsynaptic CMS
The mutation impairs postsynaptic voltage-gated sodium channel (SCN4A) 
and might cause severe respiratory distress with fluctuation of disease severity. 
Unfortunately, patients do not respond to anticholinesterases but might respond 
well to combined therapy with diaminopyridine [34, 35].
5. Childhood autoimmune myasthenia gravis
Generally, there is no significant difference in myasthenia gravis between 
patients younger than 18 years and adults in terms of pathophysiology, clinical pre-
sentation, and diagnosis [36, 37]. CMS must be considered in seronegative MG, but 
low incidence of seropositive cases in acquired MG makes the diagnosis challenge-
able. There is no female predominance with higher rate of spontaneous remission 
in prepubertal children. On other hand, there is evidence of higher prevalence of 
ocular MG in prepubertal children [38].
Although the treatment line is the same as that of adults, there is concern of 
stunted growth with steroid treatment, as well as the drawback of accumulative 
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effect of immunosuppressive drugs [39, 40]. Thymectomy is usually postponed as 
there is a possibility of spontaneous remission to happen and attempt to avoid such 
invasive procedure. Therefore, the treatment should be individualized, and gener-
ally, the treatment is often less aggressive, particularly in the prepubertal age group.
Although respiratory failure might occur in some cases, the general prognosis is 
often satisfactory.
6. Neonatal myasthenia caused by maternal MG
Maternal MG can cause transient neonatal myasthenia in about 20% of cases, 
the pathophysiology behind is AChR autoantibodies cross the placenta from the 
mother to the fetus. The neonate may have born with severe weakness to mother 
with mild MG and the invers is true, therefore, the severity of disease in neonate 
is not related to mother MG. Moreover, it is not related to the duration of maternal 
MG and can occur even in those with seronegative MG [41–44]. Nevertheless, 
the effect may have decreased with proper maternal treatment, while subsequent 
pregnancy may cause more affected neonates [45–47].
The condition is usually transient, and it presents clinically soon after birth with 
generalized weakness, difficulty in sucking and swallowing, weak cry, respiratory 
distress, which may get worse with inability to clear pharynx that may cause airway 
obstruction and cyanosis, in addition to ptosis and strabismus, but it is less common 
in older children.
The diagnosis is suspected by history of maternal MG, detection of AChR 
antibody in the infant and mother, and EMG—older children show decremental 
response with low rate of repetitive stimulation but not for high rates as decremen-
tal response occurs in high-rate stimulations in normal neonates. Furthermore, 
responding to cholinesterase inhibitors make diagnosis most likely [48].
Treatment involves cholinesterase inhibitors, in addition to supportive mea-
sures. Plasma exchange may be needed for severe, life-threatening conditions.
The prognosis fortunately is good as the syndrome is transient and improve-
ment is complete in most infants with the duration of recovery ranging from 1 week 
to 8 weeks without recurrence, which is most probably related to the clearance 
of causative autoantibodies. However, about 10% of patients may die because of 
inadequate respiratory support and delayed or improper treatment [49].
7. Conclusion
Myasthenia syndrome in children not uncommon but the unique in children is 
the inherited congenital myasthenia syndrome which is not follow autoimmune and 
no antibodies determined. Therefore, a precise diagnosis is important for treatment. 
The challenge is to differentiate this syndrome from seronegative acquired myasthe-
nia gravis and one may need, in addition to conventional investigation, specialized 
microelectrode analysis of neuromuscular transmission with or without genetic test.
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